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Among the challenges confronting patients with rare diseases is a dearth of treatment options. The development
of safe and effective new therapies is hampered by challenges associated with conducting clinical trials in small
populations. In this article, we describe how the Duchenne muscular dystrophy community–led by Parent Project
Muscular Dystrophy–created a proposed draft guidance document for industry for submission to the U.S. Food and
Drug Administration. This unprecedented undertaking involved a broad coalition of more than 80 stakeholders
collaborating across nine time zones to produce a document in only 6 months. We hope that other rare disease
communities and advocacy organizations can use our experience as a model for developing their own draft
guidance documents.
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Duchenne muscular dystrophy (Duchenne) is a genetic
disorder characterized by progressive muscle weakness
and degeneration [1–4]. It is caused by a mutation in
the gene that encodes dystrophin, a protein critical to
muscle integrity [1, 2, 4]. Boys are affected almost exclu-
sively, with an estimated incidence of approximately 1 in
every 4000 live male births [2, 4, 5].
Duchenne is typically diagnosed between 3 and 5 years
of age, following the onset of symptoms such as delayed
walking, difficulty climbing stairs, frequent falls, and dif-
ficulty running and jumping [1, 2, 4]. More than 90 % of
patients require the use of a wheelchair by their mid-
teens [5]. Weakened heart and lung muscles lead to vari-
ous cardiac and pulmonary complications (e.g., cardiomy-
opathy, difficulty breathing, respiratory infections) [2, 4].* Correspondence: Pat@parentprojectmd.org
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creativecommons.org/publicdomain/zero/1.0/Affected individuals may also have varying degrees of cog-
nitive, behavioral, or language impairment [4].
Within the last 15 years, individuals with Duchenne
did not survive much beyond their teen years [1, 2, 4].
With improvements in care, the mean lifespan has in-
creased to more than 25 years, with some patients living
into their 30s, 40s, or even 50s [1, 2, 4]. Corticosteroids
are prescribed off-label to slow the decline in muscle
strength and function; current treatment guidelines
recommend their use in all qualified individuals [4].
No drug currently has an FDA-approved indication for
Duchenne [6].
To help accelerate the development and review of po-
tential therapies for Duchenne, the Parent Project Mus-
cular Dystrophy (PPMD) spearheaded an effort to
develop the first patient advocacy-initiated draft guid-
ance for a rare disease. This report details the process
used to write the guidance, which included a broad co-
alition of more than 80 stakeholders collaborating across
nine time zones. It is our hope that other rare diseasearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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model for developing their own draft guidances.
Deciding to develop draft industry guidance
The decision to develop a draft industry guidance came
after PPMD had been working for more than a decade
to educate the FDA and other regulatory agencies about
Duchenne and its catastrophic effects on both patients
and families. Several events were pivotal in making this
decision. In March 2013, the European Medicines
Agency (EMA) issued a draft guideline for public com-
ment on the clinical investigation of medicinal products
for the treatment of Duchenne and Becker muscular
dystrophy [7]. The community stakeholders believed this
draft guideline did not adequately address the needs of the
Duchenne community. In response, PPMD convened an
expert advisory committee to develop and issue recommen-
dations about how the U.S. Food and Drug Administration
(FDA) could most effectively evaluate new therapies for
Duchenne. The committee included leading voices in aca-
demia, industry, and patient advocacy. The resulting white
paper, “Putting Patients First,” was released in April 2013
[8]. PPMD also held several meetings with the FDA about
developing a guidance for Duchenne.
In July 2013, PPMD met with FDA staff that included
Center for Drug Evaluation and Research director Janet
Woodcock. The meeting was a continuation of ongoing
efforts to provide the agency with relevant information
and data that might encourage greater flexibility in the
drug review process. One of the topics discussed was the
possibility of a guidance for industry addressing drug de-
velopment for Duchenne. The purpose of such a docu-
ment would be to assist sponsors in the clinical
development of drugs and address the FDA’s current
thinking about various issues that arise at all stages of
product development, including the types of clinical tri-
als that could be used to demonstrate efficacy and safety.
Guidance documents traditionally have been authored
by FDA staff.
During the discussion, the FDA staff acknowledged
that the agency had neither the time nor resources to
develop industry guidances for many of the rare diseases
that might benefit, including Duchenne. As an alterna-
tive, FDA staff invited PPMD to submit a proposed draft
guidance document, pursuant to language in the 2011
Good Guidance Practice (GGP) provisions [9]. A well-
written proposed draft guidance could serve as the basis
for–and hasten the development of–FDA’s own version
of an industry guidance for Duchenne.
PPMD knew this invitation could not be declined. But
given that no one outside FDA had ever developed a
guidance document for industry, accepting the invitation
meant entering uncharted territory. To begin navigating
that terrain, PPMD organized a daylong policy forummodeled on a recently concluded scientific meeting in
London. The policy forum, titled “Optimizing Clinical
Trials in Duchenne Muscular Dystrophy in the New Era
of Improved Care Standards: Guidance for the FDA,”
was held in Silver Spring, Maryland, in December 2013.
It was attended by more than 200 members of the
Duchenne community, encompassing patients, parents,
and representatives from the pharmaceutical and diag-
nostics industries, academia, clinical centers, and gov-
ernment. More than 20 FDA staff members (including
Dr. Woodcock) also attended.
The forum was structured as a mixture of scientific
presentations, roundtable discussions, and testimony
from patients, family members, and patient advocates,
focused on (1) the challenges associated with designing
and implementing clinical trials for rare diseases like
Duchenne and (2) the need to accelerate approval of
new therapies while meeting appropriate standards for
safety and efficacy. It became evident during the course
of the day that a draft industry guidance would require
input from all of the key scientists and stakeholders–es-
pecially patients and Duchenne-affected families–to en-
sure that the final product would be both evidence-
based and responsive to unmet community needs. The
forum concluded with an agreement that the Duchenne
community, led by PPMD, would work together to de-
velop the proposed draft guidance. PPMD committed to
completing the project in 6 months (see Fig. 1).
Assembling the project team
The aggressive timeline for completing the draft guid-
ance necessitated a focused “divide and conquer” strat-
egy, with content development for different parts of the
document proceeding simultaneously. The strategy
encompassed a core support team, a steering committee,
seven expert working groups, and a community advisory
board (Fig. 2).
Core support team
The core support team provided technical expertise and
managed the many moving parts of guidance develop-
ment. FaegreBD Consulting, a national firm with exten-
sive experience in regulatory affairs, provided insight
into working with the FDA and ensured that the pro-
posed draft guidance document would be in the proper
format and use appropriate terminology. Mark Krueger
& Associates, Inc. (MK&A), a firm specializing in health
care constituency relations, provided general project
management services that included defining the scope
and goals of the project, outlining participants’ responsi-
bilities, organizing meetings of the steering committee
and working groups, and ensuring the quality of all
group discussions and work products. A medical writer
with experience in treatment activism participated in all
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Fig. 1 Draft guidance project timeline
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were not already part of the steering committee, bring-
ing the total to 10.
Expert working groups
Working groups were responsible for assembling, analyz-
ing, and reporting on the body of evidence related to a
specific section of the draft guidance. To keep discussions
manageable and increase the likelihood of meeting dead-
lines, most working groups were limited to six to eight
members. All working groups had to include patient ad-
vocates, pharmaceutical industry representatives, and
Duchenne experts (e.g., physicians, basic science re-
searchers, epidemiologists). No more than three members
of a working group could come from the pharmaceutical
industry, and all were required to have appropriate and
relevant scientific, clinical, or public health experience.
The chair of each working group also was a member of
the steering committee and served as a liaison between the
working group members and the steering committee.
Chairs were permitted to invite non-members to participate
if their specialized knowledge would illuminate specific dis-
cussions (e.g., an expert in clinical trial design invited to dis-
cuss outcome measures for pulmonary disease).
Community advisory board
Although Duchenne patients, parents, and patient repre-
sentatives were included as members of the steering com-
mittee and all working groups, PPMD believed strongly
that the draft guidance must represent the diverse needs
and perspectives of the Duchenne community as much as
possible. The organization solicited participants for a
community advisory board through multiple avenues, in-
cluding extending an invitation to community members
who had attended the December 2013 policy forum, post-
ing an open invitation on the PPMD website, sending tar-
geted e-mail messages, and following up with telephone
and face-to-face meetings. The community advisory board
ultimately included 40 volunteers who reviewed the draft
guidance with an eye toward ensuring that the patient
voice was evident. The members of the Community
Advisory Board are listed in Additional file 1.
Establishing the vision
The steering committee met for the first time via tele-
conference on January 24, 2014. The members tackled
an ambitious agenda:
 Articulate the goals, objectives, and framework of
the draft guidance.
 Define topics to be addressed by working groups
and develop charges for each group.
 Outline the roles and responsibilities of working group
members and identify possible members for each group.To determine the most appropriate length and format for
the draft guidance, MK&A identified six representative FDA
guidances in five therapeutic areas: Alzheimer’s disease, hu-
man immunodeficiency virus (HIV), community-acquired
pneumonia, irritable bowel syndrome, and systemic lupus
erythematosus. A side-by-side comparison revealed an
average of 15 pages devoted to actual content (range 6–27
pages). Overlapping or common sections included an
introduction, background, general considerations, specific
efficacy trial considerations, references, and one or more
appendixes. The steering committee decided to aim for a
document that would include those sections and have 20
to 25 pages of actual content.
The steering committee identified seven theme areas
to be included in the Duchenne draft guidance and ad-
dressed by working groups. The theme areas of each
working group are detailed below:
Benefit/risk assessment analysis
This section would reflect the Duchenne community’s tol-
erance of either potential risks or uncertainty of benefit
associated with new treatment options. Benefit/risk assess-
ments typically are discussed in a few paragraphs towards
the end of guidance documents. However, the steering
committee felt that the benefit/risk ratio and patient/care-
giver preferences deserved more in-depth consideration
and positioning early in the Duchenne draft guidance. The
benefit-risk framework is the fundamental structure under
which the FDA makes regulatory decisions; putting it at the
front of the document would provide an overarching focus
for the remainder of the guidance. The steering committee
wanted to encourage clinical trial sponsors to work with
patients and parents to understand patient preferences at
the very outset and throughout the clinical development of
potential new therapies. Also, PPMD already had invested
in research to determine treatment preferences and risk tol-
erance in Duchenne [10]; the results would enable FDA to
rely more heavily on data regarding the community’s pref-
erences than on public testimony and anecdotes gathered
during New Drug Application hearings.
Diagnosis
This section would communicate problems associated
with the diagnostic delay in Duchenne and the import-
ance of genetic analysis using modern technologies, in-
cluding access to genetic testing. It also would address
the continued importance of clinical assessments in the
diagnosis and staging of Duchenne.
Natural history
This section would feature a more detailed description
of natural history than usually appears in guidance docu-
ments. The steering committee wanted to update spon-
sors and regulators on the large body of recent quality
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ical course of Duchenne, to encourage use of the infor-
mation for trial design as well as for non-concurrent
controls in novel trial designs. Specific attention would
be paid to the timing of loss of certain functional abil-
ities with current medical management, including how
Duchenne affects cardiac and pulmonary function.
Clinical trial designs, outcome measures and considerations
This section would focus on how best to evaluate new
therapies to bring them to market efficiently, while call-
ing on sponsors to design trials that include Duchenne
patients of all ages and disease stages to the extent pos-
sible. At first, this theme was intended to be addressed
by two working groups: one on outcome measures and
one on clinical trials designs. The steering committee
decided on a single working group when members real-
ized how inter-related the topics were.
Biomarkers
This section would address the large and controversial
topic of biomarkers in clinical trials of possible Duchenne
therapies. The steering committee did create two working
groups for this theme:
Muscle biopsy-based biomarkers This working group
focused on the use of biomarkers based on mutations in
the dystrophin gene, quantification of dystrophin and
muscle biopsy.
Non-muscle biopsy-based biomarkers This working
group explored emerging noninvasive techniques such
as magnetic resonance imaging and spectroscopy (MRI/
MRS).
Duchenne imperatives
This theme was not intended or expected to be a spe-
cific section in the Duchenne draft guidance. Rather, it
was intended to strengthen the patient voice throughout
the document. Several key community imperatives had
been identified during the policy forum, including the
use of placebo versus natural history controls in clinical
trials, the narrow eligibility criteria of clinical trials, and
controversies surrounding the use of dystrophin as an
endpoint in clinical trials. The steering committee
wanted a mechanism for the community to clearly voice
its position on those key issues and other matters raised
during the guidance development process.
Developing the content
With the theme areas established, the steering commit-
tee formalized the charges for the working groups and
identified possible members. Some steering committee
members were designated as working group chairs; theother chairs were selected from the list of possible group
members. The working group chairs were responsible
for contacting and inviting the members of their respect-
ive groups. The steering committee and working group
members are listed in Additional file 2.
The steering committee continued to meet monthly
via teleconference or in person through May 2014. The
two in-person meetings were scheduled to take advan-
tage of member attendance at national conferences.
Working groups met via telephone for 60 to 90 min
once or twice each month (depending on the topic) from
March to May (see Fig. 3). Before the first meeting, the
chairperson of each working group collaborated with the
medical writer on a detailed table of contents for the draft
guidance. This outline helped to ensure minimal overlap
or redundancy among sections; it also produced a de facto
discussion guide that working group members used to
focus and direct the conversation during meetings.
After each working group call, the medical writer cre-
ated text based on the discussion and deposited the
document in a shared Dropbox folder for member re-
view and comment. As text was finalized, the medical
writer edited it to ensure consistency of tone and added
it to the working version of the draft guidance.
All working groups operated under a set of guiding
principles established by the steering committee. The
guidance document needed to be fair and balanced, in-
corporating and referencing the best available evidence
while also representing the needs of patients. The
process needed to be transparent, with ample opportun-
ity for community commentary on both the direction
and content. The guidance needed to be forward think-
ing, enabling industry to expedite the development of
potential new therapies that meet high standards for
safety and efficacy. It also had to incorporate the patient
voice and encourage the use of established FDA policies
to accelerate the approval of drugs that would increase
the lifespan and improve the quality of life of patients
with Duchenne.
In keeping with these guiding principles, free and open
discussion of both published literature and current
thinking was encouraged. Leading Duchenne experts
who participated on working groups often were aware of
research in progress or data that had been presented at
scientific meetings but not published yet. Rules had to
be established for what evidence could be included in
the guidance. Steering committee members agreed that
papers in peer-reviewed journals or in press could be
cited. Other important papers that had been submitted
to medical journals and were known to be in a late stage
of review also could be cited, but they had to be marked
clearly as unpublished data.
Part of MK&A’s role was to mediate and adjudicate con-
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Fig. 3 Process for developing individual draft guidance document sections and master document
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tee wanted to avoid a situation in which a minority of
participants disagreed with the direction the guidance
document was taking and disassociated themselves
from the project (or created an alternative guidance).
Everyone involved in the process would have to stand
behind the final product, acknowledging instances in
which the literature and expert opinion did not neces-
sarily converge.
The community advisory board met via teleconference
or webinar in March, April, and May 2013 to review and
comment on materials in development. The most
current versions were posted on a password-protected
page on the PPMD website. After each meeting, the
medical writer compiled the comments and shared them
with the working groups. Each working group deter-
mined how to address and incorporate comments rele-
vant to its section.
As the complete guidance document took shape, the
medical writer collaborated with the working group
chairs on any sections deemed to need additional infor-
mation or clarification. The penultimate version was
shared with all steering committee and working group
members for a last round of review. Once all comments
were incorporated to everyone’s satisfaction, the steering
committee approved the document.
Finalizing the draft guidance
After nearly 50 revisions, the final version of the pro-
posed draft guidance for industry–titled “DuchenneMuscular Dystrophy: Developing Drugs for Treatment
over the Spectrum of Disease”–was submitted to the
FDA on June 26, 2014 (Additional file 3). At 47 pages of
content, the document was more than double the ori-
ginal target length.
The Duchenne Imperatives Working Group crafted a
cover letter for the guidance that reiterated the urgency
felt by patients and families, summarized the guidance
content, and highlighted the community’s most critical
requests (Additional file 4). These requests included
some advocacy imperatives that did not fit or appear in
the guidance, such as a call to implement routine new-
born screening for Duchenne.
At the request of the community representative on the
steering committee, the cover letter included personal
stories from several parents. These stories recounted the
heartbreak associated with watching a child’s progressive
loss of function and independence and increasing de-
pendence on family, as well as the extraordinary bur-
dens–physical, financial, emotional, and spiritual–that
Duchenne places on families and caregivers.
At the time this manuscript was prepared, it remained
unclear how much of the proposed draft guidance would
be included in FDA’s own version. The FDA accepted
the submission and held an internal meeting on August
13, 2014 to review the document. A required 30-day
public comment period began on September 4, 2014, via
an open docket. Recent conversations between PPMD
and the FDA suggest the FDA will release the FDA’s
guidance for Duchenne by the end of 2015.
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From the start of the process, the steering committee
stressed the importance of publishing PPMD’s proposed
draft guidance document in its entirety (including the
cover letter, (Additional files 3 and 4) in a medical, sci-
entific, or policy journal. Doing so would share the views
of the working groups with the entire Duchenne com-
munity and present them to other rare disease groups
for review. In addition, the steering committee felt that
publishing PPMD’s guidance document would provide
further encouragement for the FDA to integrate as many
of PPMD’s recommendations into the FDA’s own guid-
ance for industry on Duchenne.
PPMD views its submitted guidance for industry as a
living document, to be updated as new data are pub-
lished and new therapies enter the market. A formal
process for accomplishing this has not been established
yet. However, PPMD has acted opportunistically to pro-
vide additional input on pressing clinical challenges in
Duchenne management. For example, PPMD collabo-
rated with the National Institutes of Health (NIH)
National Heart, Lung and Blood Institute (NHLBI) to
convene a working group meeting in July 2014 that ex-
plored current issues relevant to cardiac disease in pa-
tients with Duchenne. Attendees included experts in
cardiology, clinical trials, patient advocacy, and FDA. A
discussion at that meeting led to questions about the
optimal cardiac surveillance practices to include in
Duchenne clinical trials. The working group developed a
position paper [11] covering responses to those ques-
tions, including recommendations for cardiac surveil-
lance in Duchenne clinical trials, and PPMD submitted
it to the FDA for inclusion as an addendum to the draft
guidance [12].
Benefits to the Duchenne community
Working together to produce the guidance resulted in a
stronger relationship between the Duchenne community,
sponsors and the FDA. The quality of the document
produced enhanced the credibility and relationship be-
tween PPMD, the FDA, sponsors and the Duchenne
community. Both the FDA and sponsors are now more
interested in obtaining the patient perspective.
This is an extension of PPMD’s previous work to in-
form the FDA’s benefit-risk assessments with concrete
data on treatment preferences and risk tolerance in
Duchenne. PPMD conducted a rigorous survey [10] of
more than 100 Duchenne caregivers. In the study, care-
givers were presented with hypothetical treatment pro-
files and asked to judge which aspects they thought were
best and worst. The results indicated that caregivers
would be willing to accept the risk of a serious side effect
if the treatment stopped or slowed the progression of
muscle weakness, even absent improvement in lifespan[10]. This study informed the FDA’s benefit–risk assess-
ments, and PPMD believes the FDA will give greater
weight to the demonstrated benefit/risk preferences of pa-
tients and caregivers when assessing and making risk–
benefit determinations in the future.
The relationship PPMD and the Duchenne community
have established with the FDA has fostered additional
collaborations to improve patient involvement in clinical
outcome measures. As mentioned above, PPMD collabo-
rated with NHLBI to explore issues relevant to cardiac
disease in Duchenne patients [12]. This collaboration de-
veloped a position paper [11] that included recommen-
dations for cardiac surveillance in Duchenne clinical
trials. PPMD and the Duchenne community continue to
encourage sponsors to work with patients to validate
current patient reported outcome measures or develop
new ones, to explore the use of exploratory outcome
measures and to support the development of novel out-
come measures. PPMD has been involved in determin-
ing how to identify outcome measures so ambulatory
and non-ambulatory Duchenne patients can participate
in clinical trials. Examples include the development of
outcome measures for upper limb strength and fatigue.
Upper limb strength can be measured with MRI, and
measurements of reachable work space interacting with
the Microsoft Kinect system. Fatigue protocols have
been developed to quantify levels of fatigue. These new
outcome measures allow sponsors to stratify patients for
inclusion criteria in clinical trials. This collaboration en-
ables sponsors to conduct clinical studies that include
individuals across the spectrum of Duchenne disease.
Implications, critical learnings and key success factors
Other groups seeking to replicate this approach to devel-
oping a draft guidance for industry need to be cognizant
of the significant time and expense involved. PPMD en-
tered the process with many advantages, including an
established relationship with key opinion leaders, the
FDA, and the resources needed to complete the project.
The success of this project is also attributed to learning
from other communities, hiring an independent project
management company and medical writer. The focus on
the guidance enabled all members of the Duchenne
community to find common ground and speak with one
voice. All of these considerations contributed to the suc-
cess of this project and are detailed below.
Access to leading experts
PPMD has always been well connected to leading basic
and clinical researchers through its medical and scien-
tific advisory board and peer-review process for grant
applications, among other routes. Leaders in the
Duchenne field already had ties to the organization and
respected its goals and programs. As a result, many were
Furlong et al. Orphanet Journal of Rare Diseases  (2015) 10:82 Page 8 of 9eager to contribute their knowledge and credibility and
willing to accept the challenge of creating the draft guid-
ance on a short timeline. In fact, PPMD had more vol-
unteers than working group spots; many difficult
decisions were made on the basis of availability during
the very short development time frame.
Credibility with regulators
PPMD has demonstrated its command of complex chal-
lenges in drug development and approval through efforts
such as “Putting Patients First” and the December 2013
public policy forum. FDA was willing to engage with
PPMD in part because of the organization’s knowledge
and rational approach, incorporating objective views and
data wherever possible.
Sufficient staff and budget
Creating the proposed draft guidance took considerable
time and patience. PPMD saw this document as a long-
term commitment and made the decision, with board ap-
proval, to invest the necessary funds. It helped considerably
that all steering committee members, working group mem-
bers, and community advisors generously volunteered their
time and effort. However, PPMD hired MK&A, an inde-
pendent project management company, and medical writer,
which added to the success of the project.
Learning from other communities
At the start of this process, PPMD reached out to other
communities, such as the HIV community, with known
experience in this area to provide guidance and advice
during this process. The HIV community was willing to
provide this information, which added to the success of
the project.
MK&A, project management company
MK&A organized all of the logistics needed to produce
the guidance in the short (6 month) timeframe. This in-
cluded helping to define the scope and goals of the pro-
ject and outlining participants’ responsibilities. MK&A
also handled all of the timelines, phone calls with com-
mittee members, scheduled all of the meetings, prepared
agendas, attended and wrote summaries of all meetings,
provided coordination between groups and ensured the
quality of all group discussions and work products. This
enabled all volunteers and the staff at PPMD to focus on
writing the guidance document.
Medical writer
The independent medical writer was provided content
from all parts of the Duchenne community. This writer
participated in all steering committee and working group
meetings, reviewed the materials and objectively devel-
oped the content included in the guidance. The resultingdocument reflects the opinions of all members of the
Duchenne community.
Consistent messaging
The Duchenne community focused around the guidance,
with a collective voice and consistent messaging. This
was an important way for all members of the Duchenne
community to work together.
PPMD and the Duchenne community realize the ur-
gency of Duchenne disease and wanted to develop the
guidance as thoroughly and quickly as possible. This com-
munity, led by PPMD, wanted to produce a quality docu-
ment that the FDA would be able to use as a draft. Hence,
the draft guidance became the priority for the Duchenne
community. Since submission of the guidance, PPMD has
received positive feedback from the FDA.
Drafting a guidance with insufficient time and expenses
PPMD notes that limited resources would have extended
the time needed for this project. It is likely that some
members of the Duchenne community may not have
been willing or able to volunteer their time for longer. It
is estimated that each volunteer spent at least 4 to 6 h
per month for 6 months on this project. Thus, produ-
cing the guidance in the most efficient manner was of
utmost importance for both the volunteers and patients.
Recommendations for other patient advocacy groups
Several factors need to be in place before a patient advo-
cacy group community should consider developing a
draft guidance. First, the disease must be characterized.
Areas of unmet need should be established and dis-
cussed with leading experts in the field, and the FDA.
Working as a partner with the FDA, PPMD has con-
ducted studies10 to provide the data needed to inform
decisions. Developing these relationships as partners in
the fight against Duchenne disease were critical to suc-
cessfully developing this guidance.
Conclusion
Developing a proposed draft guidance for industry may
represent the best opportunity for a rare disease commu-
nity to shape the way the FDA reviews new potential ther-
apies in historically challenging rare disease categories.
We hope that our experience and the model described in
this article demonstrate that such an undertaking is both
realistic and achievable.
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